History

Meppel

Delpharm continues to grow with the acquisition of the Meppel (Netherlands) site, formerly owned by Astellas. It specializes in solid oral dosage forms. With FDA certification, Delpharm has strengthened its position as a supplier to the US market.

Leiden

Delpharm expands its development activities with the acquisition of a development center for sterile injectable forms, based in Leiden (in the Netherlands).

Boucherville

In 2022, Delpharm was able to acquire the Boucherville (Canada) plant, which was owned by Novartis.
This plant allows Delpharm to offer sterile ampoules and vials in North America.

Poznań

In 2021, Delpharm was able to acquire Poznań plant, which was owned by GSK. This one allows Delpharm to add a new offer in the company’s portfolio: high potent soft gel capsules.

Creation of DELPHARM ACADEMY

DELPHARM ACADEMY’s objectives are to organise:
-  The integration of our new employees, then to encourage them in their professional development and to develop their technical expertise.
-  The training of our future employees in our professions.

Delpharm has been recognized by several Labels in terms of human resources.

Delpharm : Employment creator

Since the creation of the company, 630 employees have joined the Delpharm adventure at these 17 plants.

Acquistion of 5 new plants

2019 is a major year for Delpharm with the acquistion of 5 new plants from Famar.

Each plant has its strong asset:
-  Delpharm Bladel expands the company’s capabilities in liquid and semi-solid forms.

-  Delpharm L’Aigle allows the increase of capabilities in solid forms and more specifically sugar-coated tablets.

-  Delpharm Montréal is the first plant in North America.

-  Delpharm Orléans is a plant with more capabilities in effervescent tablets, sachets and liquid and semi-solid forms in mass production.

-  Delpharm Saint-Rémy provides a new dosage form to the group: freeze-drying.

DCAT Week

Delpharm attends for the first time to DCAT Week which is the premier business development event for companies engaged in pharmaceutical development and manufacturing and related industries.

Milano

Delpharm grows up in Italy with the acquisition of Roche Segrate plant in Milano. This one allows Delpharm to export conventional solid forms to USA with FDA agreement.

Evreux

In June 2016, Delpharm Evreux starts softgel capsules production and creates 5 new jobs for this new dosage forms.

Novara

The year 2016 allows Delpharm to acquire its second European plant, based in Novara with a new offer in the company’s portfolio: prefilled syringes packaging.

Boulogne-Billancourt

Delpharm moves to a new headquarter in Boulogne-Billancourt (92100).

Dijon

In 2015, Delpharm increases its injectables capacities thanks to Dijon plant, previously owned by Sanofi.

Gaillard

In 2012, Delpharm has the opportunity to acquire Gaillard plant, which was owned by Bayer. This plant allows the company to develop his galenical portfolio with effervescent tablets.

Huningue

Huningue plant acquisition, ex Novartis, allows Delpharm to propose semi-solids forms and more.

FDA approval

Delpharm Lille obtains FDA approval for the first time.

Reims

In 2008, Delpharm expands the dosage forms range with the acquisition of Boehringer plant, based in Reims. The company adds liquid forms to its portfolio.

Lille

Bayer Schering plant becomes Delpharm Lille in 2006 with hormones and high potent forms as core business.

Evreux

In 2002, the company acquires Evreux plant, ex Pfizer Pharmaceutical, allowing it to increase its solid forms capacities.

Brétigny

In 1994, Delpharm make the acquisition of Brétigny plant, ex Roche Synthex, which is specialised in solid forms.

Tours

Delpharm was funded by the acquisition of Tours plant which belonged to Delmas. The first dosage forms obtained by the group was injectables.